Search Result

Results for "

VEGFR2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (1) Apoptosis (51) Aurora Kinase (5) Autophagy (23) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (2) c-Fms (7) c-Kit (25) c-Met/HGFR (14) Carbonic Anhydrase (4) Casein Kinase (2) Caspase (1) CDK (4) Checkpoint Kinase (Chk) (1) Complement System (1) Dihydrofolate reductase (DHFR) (2) Discoidin Domain Receptor (2) Drug Metabolite (1) EGFR (11) Endogenous Metabolite (1) Ephrin Receptor (1) ERK (2) FAK (2) Ferroptosis (3) FGFR (28) FLT3 (20) Fungal (2) GSK-3 (2) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) HSV (1) IKK (1) Integrin (2) Interleukin Related (1) IRE1 (3) Isotope-Labeled Compounds (6) JAK (2) LRRK2 (1) MAP3K (1) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (2) Mitophagy (3) Mixed Lineage Kinase (2) mTOR (1) Necroptosis (1) NF-κB (1) PDGFR (45) PERK (1) PI3K (2) PROTACs (1) Raf (9) Reactive Oxygen Species (2) RET (10) Src (12) Syk (1) TAM Receptor (8) Tie (7) Topoisomerase (2) Trk Receptor (4) VEGFR (200)
By Research Areas:	Cancer (190) Cardiovascular Disease (16) Endocrinology (1) Infection (5) Inflammation/Immunology (18) Metabolic Disease (3)

By Targets:

Akt (1)

Antibiotic (1)

Apoptosis (51)

Aurora Kinase (5)

Autophagy (23)

Bacterial (2)

Bcl-2 Family (1)

Bcr-Abl (2)

c-Fms (7)

c-Kit (25)

c-Met/HGFR (14)

Carbonic Anhydrase (4)

Casein Kinase (2)

Caspase (1)

CDK (4)

Checkpoint Kinase (Chk) (1)

Complement System (1)

Dihydrofolate reductase (DHFR) (2)

Discoidin Domain Receptor (2)

Drug Metabolite (1)

EGFR (11)

Endogenous Metabolite (1)

Ephrin Receptor (1)

ERK (2)

FAK (2)

Ferroptosis (3)

FGFR (28)

FLT3 (20)

Fungal (2)

GSK-3 (2)

HDAC (2)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (2)

HSV (1)

IKK (1)

Integrin (2)

Interleukin Related (1)

IRE1 (3)

Isotope-Labeled Compounds (6)

JAK (2)

LRRK2 (1)

MAP3K (1)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (2)

Mitophagy (3)

Mixed Lineage Kinase (2)

mTOR (1)

Necroptosis (1)

NF-κB (1)

PDGFR (45)

PERK (1)

PI3K (2)

PROTACs (1)

Raf (9)

Reactive Oxygen Species (2)

RET (10)

Src (12)

Syk (1)

TAM Receptor (8)

Tie (7)

Topoisomerase (2)

Trk Receptor (4)

VEGFR (200)

By Research Areas:

Cancer (190)

Cardiovascular Disease (16)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (18)

Metabolic Disease (3)

224

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103002

SU5408 3 Publications Verification VEGFR2 Kinase inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-18926

VEGFR2-IN-7

VEGFR2-IN-7 (compound E) is an inhibitor of VEGFR2. VEGFR2-IN-7 can used in study cancers .
HY-147133

VEGFR2-IN-2

VEGFR Cancer

VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching
HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)

VEGFR Cancer

Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .

VEGFR2-IN-7
VEGFR2-IN-7 (compound E) is an inhibitor of *VEGFR2. VEGFR2*-IN-7 can used in study cancers .

VEGFR2-IN-2	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

Anti-Mouse VEGFR-2 Antibody (DC101)	VEGFR	Cancer
Anti-Mouse VEGFR-2 Antibody (DC101) is a potent *VEGFR2* inhibitor that can be used for the research of papilloma .

HY-145849

VEGFR2-IN-1	VEGFR	Cancer
VEGFR2-IN-1 is a potent and selective *VEGFR2* inhibitor (IC₅₀=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and *VEGFR2* inhibition .

HY-153158

VEGFR2-IN-3

VEGFR Cancer

VEGFR2-IN-3 (compound 385) is a potent VEGFR2 inhibitor .

VEGFR2-IN-3	VEGFR	Cancer
VEGFR2-IN-3 (compound 385) is a potent *VEGFR2* inhibitor .

HY-149361

VEGFR2-IN-4	VEGFR	Inflammation/Immunology
VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI₅₀ of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis .

HY-162326

VEGFR-2-IN-41	VEGFR Apoptosis	Cancer
VEGFR-2 IN-41 (Compound 8) is a *VEGFR-2* inhibitor with IC₅₀ 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .

HY-149512

FGFR1/VEGFR2-IN-1

FGFR VEGFR Cancer

FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .

FGFR1/VEGFR2-IN-1	FGFR VEGFR	Cancer
FGFR1/VEGFR2-IN-1 (compound 2b) is an *FGFR1/VEGFR2* inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .

HY-147243

Ansornitinib ANG-3070	VEGFR PDGFR	Cardiovascular Disease Inflammation/Immunology
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .

HY-146539

HDAC-IN-35

HDAC VEGFR Cancer

HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively .

HDAC-IN-35	HDAC VEGFR	Cancer
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and *VEGFR-2* inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and *VEGFR-2*, respectively .

HY-19986

AAL993	VEGFR	Cardiovascular Disease Cancer
IC₅₀s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties .

HY-100419

BFH772

VEGFR Cancer

BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM .
HY-148040

VEGFR-2-IN-29

VEGFR Cancer

VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC₅₀ of 16.5 nM .

BFH772	VEGFR	Cancer
BFH772 is a potent oral *VEGFR2* inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM .

VEGFR-2-IN-29	VEGFR	Cancer
VEGFR-2-IN-29 (Compound 5) is a *VEGFR-2* inhibitor with an IC₅₀ of 16.5 nM .

HY-108444

(Z)-FeCP-oxindole	VEGFR	Cancer
(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC₅₀ value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC₅₀ less than 1 μM .

HY-108444A

(E)-FeCP-oxindole	VEGFR	Cancer
(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC₅₀ value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC₅₀ less than 1 μM .

HY-151635

PI3K/VEGFR2-IN-1	PI3K VEGFR Apoptosis	Cancer
PI3K/VEGFR2-IN-1 is a potent dual *PI3K/VEGFR2* inhibitor with IC₅₀ values of 2.21 and 68 μM for PI3K and VEGFR2, respectively. PI3K/VEGFR2-IN-1 induces apoptosis. PI3K/VEGFR2-IN-1 can be used in research of cancer .

HY-12018

Vatalanib dihydrochloride 10+ Cited Publications PTK787 dihydrochloride; ZK-222584 dihydrochloride; CGP-797870 dihydrochloride	VEGFR Apoptosis	Cancer
Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-109020

Acrizanib

1 Publications Verification

LHA510
VEGFR Others

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .

Acrizanib 1 Publications Verification LHA510	VEGFR	Others
Acrizanib (LHA510) is a *VEGFR-2* inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .

HY-155760

hCA/VEGFR-2-IN-3	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC₅₀=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-18625

VEGFR-2-IN-5

VEGFR Cancer

VEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
HY-18625A

VEGFR-2-IN-5 hydrochloride

VEGFR Cancer

VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .

VEGFR-2-IN-5	VEGFR	Cancer
VEGFR-2-IN-5 is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

VEGFR-2-IN-5 hydrochloride	VEGFR	Cancer
VEGFR-2-IN-5 hydrochloride is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-144804

VEGFR-2-IN-17

VEGFR Cancer

VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .

VEGFR-2-IN-17	VEGFR	Cancer
VEGFR-2-IN-17 (Compound 15a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .

HY-125741

GW768505A free base	Tie VEGFR	Cancer
GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2, with a pIC₅₀ of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity 。

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-144803

VEGFR-2-IN-16

VEGFR Cancer

VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .
HY-147902

VEGFR-2-IN-24

VEGFR Cancer

VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .
HY-12038

Ki8751

3 Publications Verification

VEGFR Cancer

Ki8751 is a potent VEGFR2 inhibitor with an IC₅₀ of 0.9 nM.

VEGFR-2-IN-16	VEGFR	Cancer
VEGFR-2-IN-16 (Compound 15b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .

VEGFR-2-IN-24	VEGFR	Cancer
VEGFR-2-IN-24 is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .

Ki8751 3 Publications Verification	VEGFR	Cancer
Ki8751 is a potent *VEGFR2* inhibitor with an IC₅₀ of 0.9 nM.

HY-N8342

Rhamnazin	VEGFR	Inflammation/Immunology Cancer
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-147800

VEGFR-2-IN-21

VEGFR Cancer

VEGFR-2-IN-21 (Compound 5d) is a potent VEGFR-2 inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .
HY-131658

VEGFR-2-IN-6

VEGFR Others

VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .

VEGFR-2-IN-21	VEGFR	Cancer
VEGFR-2-IN-21 (Compound 5d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .

VEGFR-2-IN-6	VEGFR	Others
VEGFR-2-IN-6 (example 64) is a *VEGFR2* inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of *VEGFR-2, c-kit, PDGFR* with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .

HY-146491

VEGFR-2/BRAF-IN-1	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .

HY-10248

RAF265

5+ Cited Publications

CHIR-265
Raf VEGFR Autophagy Apoptosis Cancer

RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.
HY-146236

VEGFR-2-IN-27

VEGFR Cancer

VEGFR-2-IN-27 (compound 7a) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .

RAF265 5+ Cited Publications CHIR-265	Raf VEGFR Autophagy Apoptosis	Cancer
RAF265 is a potent and orally active *RAF/VEGFR2* inhibitor.

VEGFR-2-IN-27	VEGFR	Cancer
VEGFR-2-IN-27 (compound 7a) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-10203

Vatalanib

10+ Cited Publications

PTK787; ZK-222584; CGP-79787
VEGFR Cancer

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC₅₀ of 37 nM.
HY-101628

VEGFR-2-IN-9

KDR-in-4
VEGFR Cardiovascular Disease

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

Vatalanib 10+ Cited Publications PTK787; ZK-222584; CGP-79787	VEGFR	Cancer
Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

VEGFR-2-IN-9 KDR-in-4	VEGFR	Cardiovascular Disease
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

HY-145856

VEGFR-2-IN-11	VEGFR Apoptosis	Cancer
VEGFR-2-IN-11 (Compound 8h) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .

HY-146229

VEGFR-2-IN-25

VEGFR Cancer

VEGFR-2-IN-25 (compound 5d) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .
HY-15467

ZM323881

VEGFR Cancer

ZM323881 is a potent and selective VEGFR2 inhibitor with an IC₅₀ of less than 2 nM.
HY-15467A

ZM323881 hydrochloride

2 Publications Verification

VEGFR Cancer

ZM323881 hydrochloride is a potent and selective VEGFR2 inhibitor with an IC₅₀ of less than 2 nM.

VEGFR-2-IN-25	VEGFR	Cancer
VEGFR-2-IN-25 (compound 5d) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .

ZM323881	VEGFR	Cancer
ZM323881 is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of less than 2 nM.

ZM323881 hydrochloride 2 Publications Verification	VEGFR	Cancer
ZM323881 hydrochloride is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of less than 2 nM.

HY-12018A

Vatalanib hydrochloride PTK787 hydrochloride; ZK-222584 hydrochloride; CGP-797870 hydrochloride	VEGFR Apoptosis	Others
Vatalanib (PTK787; ZK-222584; CGP-797870) hydrochloride is an inhibitor of *VEGFR2/KDR* with an IC₅₀ of 37 nM .

HY-147926

VEGFR-2-IN-28	VEGFR Apoptosis	Cancer
VEGFR-2-IN-28 (compound 12c) is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.83 µM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity .

HY-144805

VEGFR-2-IN-18	VEGFR Apoptosis	Cancer
VEGFR-2-IN-18 (Compound 15d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities .

HY-13302

CP-547632	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy .

Cat. No.	Product Name	Target	Research Area

HY-P1663

ATWLPPR Peptide 1 Publications Verification	Peptides	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

Cat. No.	Product Name	Target	Research Area

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human *anti-VEGFR2* monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)

VEGFR Cancer

Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .

HY-P990147

Anti-Mouse VEGFR-2 Antibody (DC101-CP132)	Inhibitory Antibodies	Others
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits* VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits* VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0883

Gamabufotalin 4 Publications Verification Gamabufagin	Structural Classification Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	VEGFR
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-N8342

Rhamnazin	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-112234

L-Sepiapterin Sepiapterin	Alkaloids Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 ^S6K-dependent VEGFR-2 expression .

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-N3127

Orobol	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Isoflavones	Casein Kinase PI3K VEGFR
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ) .

Cat. No.	Product Name	Chemical Structure

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-15992S

BIBF 1202-13C,d3

BIBF 1202- ¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks